Adverum Biotechnologies, Inc. Logo

Adverum Biotechnologies, Inc.

Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.

ADVM | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
100 CARDINAL WAY, 94063 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Adverum Biotechnologies, Inc. is a clinical-stage company aiming to establish gene therapy as a new standard of care for highly prevalent ocular diseases. The company develops potential functional cures to restore vision and prevent blindness. Its proprietary technology is a next-generation adeno-associated virus (AAV) vector platform for intravitreal (IVT) administration. Adverum's lead program, Ixo-vec (ixoberogene soroparvovec), is an investigational treatment for wet age-related macular degeneration (wet AMD). It is designed as a single, in-office injection that transforms retinal cells into 'biofactories' to continuously produce a therapeutic protein (aflibercept), thereby aiming to eliminate the need for frequent injections and offer a durable, long-term treatment benefit.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Adverum Biotechnologies, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Adverum Biotechnologies, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Adverum Biotechnologies, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America AAPG
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886

Talk to a Data Expert

Have a question? We'll get back to you promptly.